The most commonly reported side effects of technetium tc-99m medronate include no adverse event, product measured potency issue, and urticaria, based on 80 FDA adverse event reports from 2011 to 2025. 55.0% of reports found the drug to be ineffective.
Percentages show how often each reaction appears relative to total reports for technetium tc-99m medronate.
These are voluntary reports and do not establish that technetium tc-99m medronate caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside technetium tc-99m medronate. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
36.3% of technetium tc-99m medronate adverse event reports involve female patients and 18.8% involve male patients. The largest age group is adult at 60%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking technetium tc-99m medronate when the adverse event was reported.
Technetium Tc-99m Medronate is sold under the brand name Draximage Mdp-25.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.